liver transplantation of HCC
Conditions
Interventions
Chemotherapy group:oxaliplatin therapy
Iodine[131I] Metuximab Injection group:Iodine[131I] Metuximab Injection therapy
Sorafenib group:Sorafenib therapy
Iodine[131I] Metuximab Injection combined with Sorafenib group:Iodine[131I] Metuximab Injection combined with Sorafenib herapy
Sponsors
General Hospital of the Chinese People's Armed Police Forces
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Volunteered for the research and with good compliance, cooperate with the study and sign the information consent form; 2) Aged 18~70 years; 3) No Extrahepatic metastasis.No great vessel invasion; 4) HCC confirmed by pathological examination; 5) Do not have contraindications of liver transplantation for hepatocellular carcinoma; 6) Do not have portal vein tumor thrombus; 7) Only HAb18G/CD147(+) patients join the Iodine[131I] Metuximab Injection and Iodine[131I] Metuximab Injection combined with Sorafenib group.
Exclusion criteria
Exclusion criteria: 1) Iodine preparation allergy; 2) Allergic to biological agents or under allergy; 3) Contraindications of Sorafenib; 4) Contraindications of oxaliplatin; 5) HAb18G/CD147 (-) patients can not join the Iodine[131I] Metuximab Injection and Iodine[131I] Metuximab Injection combined with Sorafenib group; 6) Patients with poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TTR; | — |
Countries
China
Contacts
Public ContactChen Xinguo
General Hospital of the Chinese People's Armed Police Forces
Outcome results
None listed